August 28, 2018

COM-2018-016

Dear provider of pharmaceutical services,

Recall: Hydrochlorothiazide Tablets USP 12.5 Mg

At PharmPix we are committed to the health and well-being of patients. It is for this reason that we inform that on August 27, 2018 the US Food and Drug Administration (FDA) issued a statement notifying voluntary retirement of one lot of Hydrochlorothiazide Tablets USP 12.5mg manufactured by Accord. The recall was made due to labeling mix-up, a 100-count bottle of Hydrochlorothiazide Tablets USP 12.5mg has been found to contain 100 Spironolactone Tablets USP 25 mg. The affected lot is detailed on Table 1.

Table 1. Affected lot of Hydrochlorothiazide Tablets USP 12.5mg

Product	Affected Lot	NDC
Hydrochlorothiazide Tablets USP 12.5mg	PW05264	16729-182-01

The Pharmacy must:

1. Identify if they have the product in inventory and immediately stop using and dispensing the product.
2. It is important that pharmacy contact all members that in the previous 90 days received the recalled medication.
3. For questions regarding this recall can contact Accord Healthcare, Inc. by phone at 1-855-869-1081, fax: 1-817-868-5362 or e-mail at exrecalls@inmar.com.

For additional information visit:
https://www.fda.gov/Safety/Recalls/ucm618583.htm

Department of Clinical Pharmacy

CHANGING THE WAY PBM's WORK, NOW AND FOREVER